Victor Ambros and Gary Ruvkun’s Groundbreaking Research on Gene Regulation Paves the Way for Novel Cancer Treatments
The 2024 Nobel Prize in Physiology or Medicine has been awarded to American scientists Victor Ambros and Gary Ruvkun for their discovery of microRNA, a small genetic material that regulates gene expression at the cellular level. Their breakthrough offers new insights into disease treatment, including cancer. MicroRNA has the potential to both treat illnesses and serve as biomarkers for diagnosis. Though clinical trials are underway, no drugs targeting microRNA have yet been approved. This discovery is considered pivotal in advancing precision medicine, particularly in altering gene behaviors to combat diseases like cancer.
Ambros and Ruvkun, who conducted their research at Harvard University and Massachusetts General Hospital respectively, were praised for their contribution to understanding how genes function and their ability to control gene activity. Their findings hold promise for future therapeutic approaches. Dr. Claire Fletcher from Imperial College London noted that microRNA-based treatments could help stop mutated genes that cause cancer from functioning excessively.
While practical applications are still emerging, experts predict that microRNA-targeted therapies may reach patients within the next decade, marking a new era of gene-focused medicine.
The announcement marks the beginning of the 2024 Nobel Prize season, which continues this week with awards in physics, chemistry, literature, and peace.
